Posts Tagged ‘patient outcomes’

Elevated platelet count linked to negative peritoneal mesothelioma patient outcomes

7 Apr 2017 by Sarah Mahan under Research/Treatment

587px Researcher looks through microscope 1 100x100 Elevated platelet count linked to negative peritoneal mesothelioma patient outcomesThrombocytosis, a disorder that causes the body to produce too many blood platelets, has a negative impact on the success of a preferred treatment protocol for a number of mesothelioma patients, according to a new study by the University of Maryland School of Medicine. (more…)


Extrapleural pneumonectomy ‘clinically ineffective,’ group says

14 Mar 2017 by Sarah Mahan under Research/Treatment

lungs 1 002 100x100 Extrapleural pneumonectomy clinically ineffective, group saysA work group commissioned by the European Association for Cardio-Thoracic Surgery says enough evidence now exists to advise mesothelioma patients against extrapleural pneumonectomy (EPP). (more…)


Overall survival time is best clinical trial outcome measurement, study says

21 Feb 2017 by Sarah Mahan under Research/Treatment

598px Chemotherapy vials 3 100x100 Overall survival time is best clinical trial outcome measurement, study says Clinical trials are a vital part of medical testing, and their results determine treatment options for those diagnosed with an array of diseases. For those with mesothelioma, a deadly cancer caused by exposure to that affects the lining of the heart, lungs or abdomen, the results of clinical trials can determine how much longer a patient has to live.

A new study published in the journal The Oncologist stresses the important differences between two ways clinical trials determine outcomes for mesothelioma patients, according to Mesothelioma Research News. (more…)


New drug could reduce DNA modifications, improve mesothelioma patient outcomes

26 Jan 2017 by Sarah Mahan under Research/Treatment

640px DNA methylation 100x100 New drug could reduce DNA modifications, improve mesothelioma patient outcomes A new drug holds the potential to remove DNA modifications often associated with cancer cells and  decrease treatment resistance to improve patient outcomes.

Mesothelioma Research News reports drug 5-aza-dC has been found in a recent study to reduce DNA methylation, a common gene “signaling tool that locks the genes in the ‘off’ position,” according to Nature Education, and could possibly “improve the effectiveness of anti-cancer drugs and reduce the most aggressive mesothelioma cells that are often associated with treatment resistance.” (more…)


FASL gene along with platinum-based chemo could allow doctors to predict how long mesothelioma takes to progress, study says

5 Jan 2017 by Sarah Mahan under Research/Treatment

Catheter for chemotherapy 1 100x100 FASL gene along with platinum based chemo could allow doctors to predict how long mesothelioma takes to progress, study saysFor geneticists, the key to a person’s future is found on the microbiological level, and a recent Egyptian study has harnessed that insight to determine if certain genes can help predict mesothelioma patient outcomes.

Though multimodal treatment, including a combination of surgery, chemotherapy and radiation, can significantly improve a mesothelioma patient’s survival time, most diagnoses occur at later stages, when it is far too late for surgery and the talk turns to treatment options and how long a patient has to live.

Researchers in a new Egyptian study believe they have found a gene — FASL-844 CC — that can help predict how long a patient with mesothelioma can survive without disease progression, according to Mesothelioma Research News. (more…)